Catalyst Wire Dossier Catalyst Wire Dossier

ambrisentan (brand name may be marketed as Letairis or marketed as ambrisentan generic depending on region)

ambrisentan · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ambrisentan (brand name may be marketed as Letairis or marketed as ambrisentan generic depending on region), covering 2020-08-06 to 2020-08-06. Get the full timeline:

Most recent: Clinical Trial Update: Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants [Phase 1]

See pricing